Evidence map›Paper›PMID 18327581›Full record

Trial reportCancer immunology, immunotherapy : CII2008

Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis.

Lisa M Thornton, Barbara L Andersen, William E Carson

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Psychosocial risk and management of physical diseases.Journal of behavioral medicine · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lisa M ThorntonDepartment of Psychology, Ohio State University, Columbus, OH, 43210, USA. thornton.84@osu.edu
Barbara L Andersen
William E Carson

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
University of Iowa Clinical and Translational Science Program (TL1)UL1RR025755 · NCRR · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2008 to 2011
$26.3M
YOGA, IMMUNE FUNCTION, AND HEALTHM01RR000034 · NCRR · OHIO STATE UNIVERSITY · PI PESAVENTO, TODD · 1985 to 2008
$22.7M
Psychological intervention for women with breast cancerR01CA092704 · NCI · OHIO STATE UNIVERSITY · PI ANDERSEN, BARBARA L. · 2001 to 2005
$4.2M
Biobehavioral Responses to CancerK05CA098133 · NCI · OHIO STATE UNIVERSITY · PI ANDERSEN, BARBARA L. · 2004 to 2014
$1.5M
PSYCHOLOGICAL INTERVENTION FOR WOMEN WITH BREAST CANCERR01MH051487 · NIMH · OHIO STATE UNIVERSITY · PI ANDERSEN, BARBARA L. · 1996 to 2000
$791k
NCI NIH HHS K05 CA098133NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA16058NCI NIH HHS R01 CA092704NCI NIH HHS R01 CA92704NCRR NIH HHS M01 RR000034NCRR NIH HHS M01-RR0034NCRR NIH HHS UL1 RR025755NIMH NIH HHS 1 R01 MH51487NIMH NIH HHS R01 MH051487
6 · The paper itself

Abstract

backgroundA period of tumor growth precedes the clinical detection of breast cancer recurrence. We explore immune, endocrine, and behavioral parameters during this period.

methodsWe conducted a phase III clinical trial in which women with surgically treated stage II/III breast cancer (N = 227) were randomized to receive a psychological intervention or assessment-only and then regularly assessed for 10 years. Patients who recurred (R, n = 48) were matched with patients remaining disease-free (DF, n = 48) on demographic and prognostic characteristics, treatment, and duration of disease-free follow-up. Data at three assessment points, occurring, on average, 17, 11, and 4 months before the recurrence was detected clinically, with equivalent time points for the disease-free group, were examined. Mixed-effects models tested for group differences in immune cell counts and function as well as endocrine and behavioral parameters.

resultsIn the 17 months prior to recurrence detection, patients exhibited higher white blood cell count, neutrophil, lymphocyte, and natural killer cell counts, relative to DF patients. R patients also showed higher cortisol, worse physical functioning, fatigue, and quality of life. Follow-up analyses showed patients with local recurrences to differ from those with distant recurrence, with the former exhibiting elevated natural killer cell cytotoxicity, lymphocyte proliferative response, fatigue, pain, and emotional distress (depression, anxiety), and the latter exhibiting higher neutrophil, lymphocyte, and natural killer cell counts.

conclusionPatients who would recur showed reliable biobehavioral alterations more than a year prior to their diagnosis. This novel observation may contribute to our understanding of the disease relapse processes.

Indexed as

Adrenocorticotropic HormoneBreast NeoplasmsCase-Control StudiesCytotoxicity, ImmunologicDepressionEpinephrineFatigueFemaleHumansHydrocortisoneLeukocyte CountMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalNorepinephrineQuality of LifeAdrenocorticotropic HormoneEpinephrineHydrocortisoneNorepinephrine

Identifiers

PMID18327581
PMCPMC2574681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.